Menu
Not yet recruiting NCT07599956

Artificial Intelligence to Scale Early Rheumatic Heart Disease Detection

No phase Interventional Rheumatic Heart Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AI assisted echocardiography.
Who it may be relevant to
Registry conditions: Rheumatic Heart Disease. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Uganda
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The main goal of this project is to see if RADAR (Rapid AI-assisted Detection and Analysis of Rheumatic heart disease), which is a machine and deep-learning AI model, can help make rheumatic heart disease (RHD) screening easier to expand. Specifically, the project will test whether RADAR can screen as accurately-or more accurately-than current methods, and whether it can be used effectively in different low-resource settings. The aim is to show that RADAR could be adopted and used widely around the world.

Interventions

  • Diagnostic test AI assisted echocardiography
    Continue standard of care with AI-assisted echocardiography

Primary outcome measures

  • Accuracy of Provider RHD Screening [Time frame: 1 year]
Secondary outcome measures (1)
  • Interpretation Sensitivity [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Employed at a participating ADUNU facility
  • Holds a designated role in the ADUNU program as a nurse screener

Exclusion criteria

  • None. The pragmatic trial design includes all eligible staff at participating facilities.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Diagnostic

Study locations

Uganda · 1 center
  • Uganda Heart Institute — Kampala

Identifiers

NCT: NCT07599956 · 2026-0304

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗